Chimeric peptide-engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.08.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Rongrong Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Affiliated Hospital, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School…. Hauptthemen laut MEDLINE: Photochemotherapy, Immunotherapy, Photosensitizing Agents, Endoplasmic Reticulum. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
The combination of therapy-induced immunogenic cell death (ICD) and immune checkpoint blockade can provide a mutually reinforced strategy to reverse the poor immunogenicity and immune escape behavior of tumors. In this work, a chimeric peptide-engineered immunostimulant (ER-PPB) is fabricated for endoplasmic reticulum (ER)-targeted photodynamic immunotherapy against metastatic tumors. Among which, the amphiphilic chimeric peptide (ER-PP) is composed of ER-targeting peptide FFKDEL, hydrophilic PEG8 linker and photosensitizer protoporphyrin IX (PpIX), which could be assembled with a PD-1/PD-L1 blocker (BMS-1) to prepare ER-PPB. After passively targeting at tumor tissues, ER-PPB will selectively accumulate in the ER. Next, the localized PDT of ER-PPB will produce a lot of ROS to destroy the primary tumor cells, while increasing the ER stress to initiate a robust ICD cascade. Moreover, the concomitant delivery of BMS-1 can impede the immune escape of tumor cells through PD-1/PD-L1 blockade, thus synergistically activating the immune system to combat metastatic tumors. In vitro and in vivo results demonstrate the robust immune activation and metastatic tumor inhibition characteristics of ER-PPB, which may offer a promising strategy for spatiotemporally controlled metastatic tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Affiliated Hospital, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 5…
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, PR China.
Zitieren
APA
Zheng, R., Yang, N., Li, Q., Chen, Z., Huang, C., Zhao, L., Chen, X., & Li, S. (2024). Chimeric peptide-engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.013
Vancouver
Zheng R, Yang N, Li Q, Chen Z, Huang C, Zhao L, et al. Chimeric peptide-engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.013
BibTeX
@article{Zheng2024,
author = {Zheng, Rongrong and Yang, Ni and Li, Qiuyuan and Chen, Zuxiao and Huang, Chuyu and Zhao, Linping and Chen, Xin and Li, Shiying},
title = {Chimeric peptide-engineered immunostimulant for endoplasmic reticulum targeted photodynamic immunotherapy against metastatic tumor},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.08.013}
}
EUVIMED